Extremely potent and highly selective non-peptide CCK2
silent antagonist (Ki
values are 68 pM and 63 nM at CCK2
receptors respectively). Acts in vivo
to potently inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation with a long duration of action.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Small synthetic ligands of the cholecystokinin-B/gastrin receptor can mimic the function of endogenous peptide hormones.
Beinborn et al.
Yale J.Biol.Med., 1998;71:337
Long-lasting cholecystokinin2 receptor blockade after a single subcutaneous injection of YF476 or YM022.
Kitano et al.
Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro
Nishida et al.
The citations listed below are publications that use Tocris products. Selected citations for YM 022 include:
Showing Results 1 - 4 of 4